Docetaxel Injection, Solution
Product Images NDC 0409-5068

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0409-5068). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Docetaxel 01)

Chemical structure of Docetaxel, showing its detailed molecular arrangement with atoms and bonds, including its water of hydration (3 H2O) groups.*

FDA Label Image

Figure 1 (Docetaxel 02)

A Kaplan-Meier curve displaying disease-free survival (DFS) probability over time in months for two treatment groups labeled TAC and FAC. The y-axis shows DFS probability percentage from 0 to 100%, and the x-axis shows disease-free survival time up to 66 months. The graph compares survival outcomes between these groups.*

FDA Label Image

Figure 2 (Docetaxel 03)

A Kaplan-Meier survival curve chart titled 'Figure 2 - TAX316 Overall Survival K-M Curve' displaying survival probability percentage over survival time in months for two groups labeled TAC and FAC. The x-axis shows survival time from 0 to 72 months, and the y-axis shows survival probability from 0 to 100%. The solid line represents TAC and the dashed line represents FAC.*

FDA Label Image

Figure 3 (Docetaxel 04)

A Kaplan-Meier survival curve graph comparing Docetaxel 75 mg/m² (T75) versus Best Supportive Care (BSC). The x-axis shows survival time in months, and the y-axis shows cumulative probability of survival. The graph includes a log-rank p-value of 0.010 indicating overall survival comparison between treatments.*

FDA Label Image

Figure 4 (Docetaxel 05)

A Kaplan-Meier survival curve chart comparing Docetaxel 75 mg/m² (T75) versus Vinorelbine or Ifosfamide control (V/I). The chart plots cumulative probability on the y-axis and survival time in months on the x-axis, illustrating overall survival over a period of 21 months. A log-rank p-value of 0.13 is indicated for overall survival comparison.*

FDA Label Image

Figure 5 (Docetaxel 06)

A Kaplan-Meier survival curve graph titled 'Figure 5 - TAX327 Survival K-M Curves' showing survival probability over 30 months. The Y-axis represents survival probability from 0 to 1, and the X-axis shows survival time in months from 0 to 30. Two survival curves are depicted: a solid line for 'T75 q3w' and a dotted line for 'M q3w', with the T75 q3w group showing higher survival probability over time compared to the M q3w group.*

FDA Label Image

Figure 6 (Docetaxel 07)

A Kaplan-Meier curve showing time to progression in a gastric cancer study (TAX325). The graph plots probability (%) on the vertical axis against time in months on the horizontal axis, comparing two treatment groups labeled TCF and CF over 24 months.*

FDA Label Image

Figure 7 (Docetaxel 08)

A Kaplan-Meier survival curve from a gastric cancer study (TAX325) comparing survival probability over time (months) between two treatment groups labeled TCF and CF. The y-axis shows survival probability percentage, and the x-axis shows survival time up to 36 months.*

FDA Label Image

Figure 8 (Docetaxel 09)

A Kaplan-Meier curve titled 'TAX323 Progression-Free Survival K-M Curve' showing progression-free survival probability (%) on the y-axis over progression-free survival time in months on the x-axis. Two curves are displayed: a solid line labeled TPF and a dashed line labeled PF, representing different treatment groups' progression-free survival rates over time.*

FDA Label Image

Figure 9 (Docetaxel 10)

A Kaplan-Meier survival curve chart titled 'Figure 9 - TAX323 Overall Survival K-M Curve' showing survival probability (%) on the vertical axis and survival time (months) on the horizontal axis. Two curves are plotted: one solid line labeled 'TPF' and one dash-dotted line labeled 'PF', illustrating overall survival probabilities over time.*

FDA Label Image

Figure 10 (Docetaxel 11)

A Kaplan-Meier curve labeled 'Figure 10 - TAX324 Overall Survival K-M Curve' showing survival probability (%) on the y-axis and survival time in months on the x-axis. Two groups are plotted: TPF (solid line) and PF (dashed line), with sample sizes of 255 and 246 patients respectively. The number of patients at risk is displayed below the x-axis for both groups at various time points up to 72 months.*

FDA Label Image

Logo (Docetaxel 12)

FDA Label Image

Logo (Docetaxel 13)

FDA Label Image

Principal Display Panel (1 mL Vial Label)

Label for Docetaxel Injection USP 20 mg/mL intravenous solution, single-dose vial by Hospira, Inc. Includes directions to discard unused drug, storage instructions between 2°C and 8°C, and a cautionary note about the drug being a cytotoxic agent. The label displays product volume of 1 mL and contains lot and expiration date fields.*

FDA Label Image

Principal Display Panel (1 mL Vial Carton)

Packaging label for Docetaxel Injection, USP 20 mg/mL by Hospira, Inc. The label includes dosage form as an intravenous injection solution, warnings to keep out of reach of children, and instructions indicating the product is ready to add to infusion solution. The label also features a caution for cytotoxicity and barcode information.*

FDA Label Image

Principal Display Panel (4 mL Vial Label)

Label for Docetaxel Injection USP 80 mg/4 mL (20 mg/mL) sterile solution for injection, packaged in a 4 mL multiple-dose vial. The label indicates it is for intravenous use only, with a warning to check concentration prior to preparation. The labeler is Hospira, Inc., and the National Drug Code is 0409-5068-01.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Label for Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) intravenous injection solution by Hospira, Inc. The multi-dose vial label indicates the product is ready to add to infusion solution and contains 20 mg/mL Docetaxel. It includes dosage preparation warnings and storage instructions, highlighting cytotoxic caution and single-vial formulation details.*

FDA Label Image

Principal Display Panel (8 mL Vial Label)

Label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) intravenous injection solution by Hospira, Inc. The label indicates it is a sterile, multiple-dose vial with instructions to add to infusion solution and prepare prior to use. It includes lot and expiration placeholders and a barcode.*

FDA Label Image

Principal Display Panel (8 mL Vial Carton)

Packaging label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) intravenous solution by Hospira, Inc. The label shows a multiple-dose vial with instructions indicating the product is ready to add to infusion solution. It includes cautions for cytotoxicity, storage conditions, and a note to check concentration prior to preparation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.